| scholarly article | Q13442814 |
| P50 | author | Nikolaos A. Peppas | Q7024933 |
| P2093 | author name string | Julia E Vela Ramirez | |
| Lindsey A Sharpe | |||
| P2860 | cites work | Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity | Q82267419 |
| TLRs regulate the gatekeeping functions of the intestinal follicle-associated epithelium | Q82878938 | ||
| Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response | Q83104133 | ||
| In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A | Q83537857 | ||
| Cholera vaccines: WHO position paper | Q83941810 | ||
| Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant-delivery system | Q87760104 | ||
| Enhancing Oral Vaccine Potency by Targeting Intestinal M Cells | Q21089613 | ||
| Environmental enteropathy: critical implications of a poorly understood condition. | Q24606211 | ||
| Micro- and macrorheology of mucus | Q24643968 | ||
| Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy | Q27022146 | ||
| Food-associated stimuli enhance barrier properties of gastrointestinal mucus | Q27329920 | ||
| Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy | Q27488746 | ||
| Vaccines: the Fourth Century | Q27490454 | ||
| Physiological parameters for oral delivery and in vitro testing | Q27687044 | ||
| Liposomes as nanomedical devices | Q28088315 | ||
| Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria | Q28204776 | ||
| Child undernutrition, tropical enteropathy, toilets, and handwashing | Q28259147 | ||
| Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C | Q28270392 | ||
| Needle-free vaccine delivery | Q28303773 | ||
| Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response | Q28506068 | ||
| Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages | Q28594887 | ||
| Vaccine hesitancy: an overview | Q28659815 | ||
| Immunology of Gut Mucosal Vaccines | Q28972559 | ||
| Lectin-bearing polymerized liposomes as potential oral vaccine carriers | Q71729147 | ||
| The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo | Q73727591 | ||
| Medicine. The intangible value of vaccination | Q74593158 | ||
| An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells | Q79754770 | ||
| Enhancement of T-helper type I immune responses against hepatitis B surface antigen by LPS derivatives adjuvanted liposomes delivery system | Q79783376 | ||
| Oral tolerance | Q80945963 | ||
| Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination | Q81599373 | ||
| Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives | Q81919301 | ||
| PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B | Q82224193 | ||
| Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins | Q37789144 | ||
| Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns | Q37800358 | ||
| Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines | Q37860707 | ||
| Classification and functions of enteroendocrine cells of the lower gastrointestinal tract | Q37868714 | ||
| Gut-associated lymphoid tissues for the development of oral vaccines | Q37914349 | ||
| New insights in mucosal vaccine development. | Q37956429 | ||
| Towards tailored vaccine delivery: needs, challenges and perspectives. | Q37975885 | ||
| Crossing the barrier: Targeting epithelial receptors for enhanced oral vaccine delivery. | Q37986978 | ||
| PLGA-based nanoparticles: an overview of biomedical applications. | Q37986980 | ||
| The effect of nanoparticle size, shape, and surface chemistry on biological systems | Q38004588 | ||
| Vaccine delivery carriers: insights and future perspectives. | Q38007823 | ||
| Targeting nanoparticles to dendritic cells for immunotherapy | Q38008485 | ||
| Vaccines against mucosal infections | Q38009608 | ||
| Recent progress in mucosal vaccine development: potential and limitations | Q38029250 | ||
| Rotavirus vaccination: a concise review | Q38033657 | ||
| Engineering synthetic vaccines using cues from natural immunity | Q38154804 | ||
| Basics and recent advances in peptide and protein drug delivery | Q38162494 | ||
| Intestinal epithelial cells: regulators of barrier function and immune homeostasis | Q38190874 | ||
| Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012. | Q38193651 | ||
| A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules | Q38237549 | ||
| Oral delivery of nanoparticle-based vaccines. | Q38243119 | ||
| Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives | Q38259140 | ||
| Delivery strategies to enhance oral vaccination against enteric infections. | Q38393940 | ||
| Advances and challenges in mucosal adjuvant technology | Q38417265 | ||
| Strategies intended to address vaccine hesitancy: Review of published reviews | Q38431976 | ||
| Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies | Q38461061 | ||
| Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. | Q38544598 | ||
| Single-injection vaccines: Progress, challenges, and opportunities | Q38562819 | ||
| Bilosomes in the context of oral immunization: development, challenges and opportunities. | Q38796391 | ||
| Vaccine technologies: From whole organisms to rationally designed protein assemblies | Q38806558 | ||
| Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines? | Q38886698 | ||
| Development and characterization of alginate coated low molecular weight chitosan nanoparticles as new carriers for oral vaccine delivery in mice. | Q38912153 | ||
| Surface-modified P(HEMA-co-MAA) nanogel carriers for oral vaccine delivery: design, characterization, and in vitro targeting evaluation | Q38982074 | ||
| Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR. | Q39065887 | ||
| Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection | Q39079605 | ||
| The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania | Q39090135 | ||
| Recent advances with liposomes as pharmaceutical carriers | Q29616702 | ||
| Retinoic acid imprints gut-homing specificity on T cells | Q29619126 | ||
| Protein instability in poly(lactic-co-glycolic acid) microparticles. | Q30327666 | ||
| Administration strategies for proteins and peptides. | Q30369113 | ||
| Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization. | Q30371162 | ||
| Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery | Q30391507 | ||
| Immunostimulating complexes (ISCOMs) for nasal vaccination | Q30702631 | ||
| Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg | Q33212140 | ||
| M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. | Q33307430 | ||
| Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin | Q33624306 | ||
| New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development | Q33628356 | ||
| Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses | Q33710195 | ||
| Oral vaccine delivery | Q33852928 | ||
| Gut instincts: thoughts on intestinal epithelial stem cells | Q33936387 | ||
| Vaccination strategies for mucosal immune responses | Q33975703 | ||
| Human intestinal M cells display the sialyl Lewis A antigen. | Q34000445 | ||
| Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells | Q34000967 | ||
| Control of adenovirus acute respiratory disease in U.S. Army trainees | Q34040015 | ||
| Rationalizing the development of live attenuated virus vaccines | Q34119676 | ||
| Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines | Q34186333 | ||
| Delivery systems for penetration enhancement of peptide and protein drugs: design considerations | Q34190362 | ||
| M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses | Q34194207 | ||
| Survey of the prevalence of immunization non-compliance due to needle fears in children and adults | Q34278473 | ||
| Adenoviruses as vaccine vectors | Q34353523 | ||
| Vaccine adjuvants: current state and future trends | Q34358206 | ||
| Mucosal immunity and vaccines | Q34409172 | ||
| Liposomes as vaccine delivery systems: a review of the recent advances | Q34418761 | ||
| Regional specialization within the intestinal immune system | Q34439411 | ||
| Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery | Q34455041 | ||
| A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines | Q34463522 | ||
| The intestinal epithelial stem cell | Q34488153 | ||
| Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice | Q34580095 | ||
| Digestion of Nucleic Acids Starts in the Stomach | Q34671611 | ||
| Hydrogels and scaffolds for immunomodulation | Q34725541 | ||
| Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues | Q37153923 | ||
| Gut instincts: explorations in intestinal physiology and drug delivery | Q37207716 | ||
| Immunomodulatory biomaterials | Q37228960 | ||
| Vaccine adjuvants: current challenges and future approaches. | Q37244036 | ||
| Dual role of commensal bacteria in viral infections. | Q37336613 | ||
| Delivery systems: a vaccine strategy for overcoming mucosal tolerance? | Q37354182 | ||
| Barrier properties of mucus | Q37365829 | ||
| Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule | Q37435066 | ||
| Mucosal vaccines: novel advances in technology and delivery | Q37559647 | ||
| What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? | Q37634790 | ||
| Subsets of migrating intestinal dendritic cells | Q37700852 | ||
| Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination | Q37762031 | ||
| The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system | Q34798439 | ||
| Liposomal delivery of CTL epitopes to dendritic cells | Q34995214 | ||
| Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene | Q34996554 | ||
| Emerging Trends in Oral Delivery of Peptide and Protein Drugs | Q35570636 | ||
| Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies | Q35684362 | ||
| CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections | Q35713871 | ||
| Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers | Q35877982 | ||
| The mucosal immune system: from fundamental concepts to vaccine development | Q35897681 | ||
| Enteropathies in the developing world: neglected effects on global health | Q35910518 | ||
| Vaccine policy changes and epidemiology of poliomyelitis in the United States | Q35916018 | ||
| Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease | Q35952794 | ||
| ISCOM-based vaccines: the second decade. | Q36062124 | ||
| Current management of the gastrointestinal complications of systemic sclerosis | Q36068493 | ||
| Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea | Q36166749 | ||
| A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses | Q36229159 | ||
| Effects of flagellin on innate and adaptive immunity | Q36240129 | ||
| Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. | Q36266985 | ||
| Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection | Q36331205 | ||
| Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems | Q36393458 | ||
| Mucosal vaccines: the promise and the challenge | Q36402244 | ||
| Epithelial antimicrobial defence of the skin and intestine | Q36584725 | ||
| Is the oral route possible for peptide and protein drug delivery? | Q36601912 | ||
| Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study | Q36621905 | ||
| Delivery systems and adjuvants for oral vaccines. | Q36640326 | ||
| Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques | Q36665647 | ||
| Vaccine delivery using nanoparticles. | Q36712817 | ||
| Chitosan nanoparticles for oral drug and gene delivery | Q36920450 | ||
| Approaches for enhancing oral bioavailability of peptides and proteins | Q36922557 | ||
| Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium | Q36940409 | ||
| Perspectives on mucosal vaccines: is mucosal tolerance a barrier? | Q36975607 | ||
| Bridging the knowledge gaps in vaccine design | Q37027137 | ||
| Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1. | Q37069755 | ||
| Nanotechnology in vaccine delivery | Q37104199 | ||
| Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant | Q37109519 | ||
| Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. | Q39096113 | ||
| Occupational exposure to needlestick injuries and hepatitis B vaccination coverage among health care workers in Egypt | Q39506795 | ||
| Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes | Q39828748 | ||
| Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination | Q39857755 | ||
| PLGA-microencapsulation protects Salmonella typhi outer membrane proteins from acidic degradation and increases their mucosal immunogenicity | Q40098674 | ||
| PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination | Q40116447 | ||
| TLR2 activation by proteosomes promotes uptake of particulate vaccines at mucosal surfaces | Q40117050 | ||
| A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus | Q40263198 | ||
| Viral vaccination via the mucosal routes. | Q40290506 | ||
| Vaccine impact: Benefits for human health | Q40521168 | ||
| Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine | Q40632057 | ||
| Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee | Q40765461 | ||
| Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area | Q40776571 | ||
| Rational Design of Targeted Next-Generation Carriers for Drug and Vaccine Delivery | Q40825318 | ||
| Liposome: classification, preparation, and applications | Q41049173 | ||
| An oral B subunit: whole cell vaccine against cholera | Q41131326 | ||
| A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. | Q41203495 | ||
| Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination | Q41454449 | ||
| Utilizing bacterial mechanisms of epithelial cell entry: invasin-induced oral uptake of latex nanoparticles | Q41486623 | ||
| A lipid based multi-compartmental system: Liposomes-in-double emulsion for oral vaccine delivery. | Q41603951 | ||
| Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms | Q41714891 | ||
| The intestinal epithelial stem cell: the mucosal governor | Q41722535 | ||
| Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation | Q42117985 | ||
| Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. | Q42603653 | ||
| M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes | Q43260027 | ||
| Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). | Q43562176 | ||
| Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice | Q43623067 | ||
| Targeting polymerised liposome vaccine carriers to intestinal M cells | Q43745138 | ||
| A novel mucosal vaccine targeting Peyer's patch M cells induces protective antigen-specific IgA responses | Q43990531 | ||
| Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization | Q44053148 | ||
| Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans | Q44168559 | ||
| Liposomal delivery of antigen to human dendritic cells | Q44290945 | ||
| Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis | Q44681127 | ||
| Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs | Q44735346 | ||
| Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres | Q44842072 | ||
| Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. | Q45962430 | ||
| Shape and size-dependent immune response to antigen-carrying nanoparticles | Q46184185 | ||
| Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. | Q46564597 | ||
| Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype | Q47097020 | ||
| Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization | Q47345484 | ||
| Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin | Q47356240 | ||
| Reduction of Salmonella enteritidis number after infections by immunization of liposome-associated recombinant SefA. | Q50005290 | ||
| Complexation hydrogels as potential carriers in oral vaccine delivery systems. | Q51090494 | ||
| Optimism over vaccines administered via mucosal surfaces. | Q51097653 | ||
| Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles. | Q51455396 | ||
| Development of stabilized glucomannosylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery. | Q51750508 | ||
| Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. | Q51769095 | ||
| Investigation of 3-D ordered materials with a high adsorption capacity for BSA and their potential application as an oral vaccine adjuvant. | Q53461562 | ||
| Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in-vitro and in-vivo characterization. | Q53632592 | ||
| Re-born in the USA: Another cholera vaccine for travellers | Q56514978 | ||
| Adipose Tissue Engineering Using Injectable, Oxidized Alginate Hydrogels | Q57782403 | ||
| Development of an Advanced Intestinal in Vitro Triple Culture Permeability Model To Study Transport of Nanoparticles | Q58200378 | ||
| Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles | Q58854014 | ||
| A recombinant human adenovirus vaccine against rabies | Q64378826 | ||
| Anatomy and physiology of the gastrointestinal tract | Q70007605 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 116-131 | |
| P577 | publication date | 2017-04-21 | |
| P1433 | published in | Advanced Drug Delivery Reviews | Q2825362 |
| P1476 | title | Current state and challenges in developing oral vaccines | |
| P478 | volume | 114 |
| Q64068510 | Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines |
| Q56889010 | Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases |
| Q55006868 | Biomimetic thiamine- and niacin-decorated liposomes for enhanced oral delivery of insulin. |
| Q90573359 | Critical Role of B Cells in Toll-Like Receptor 7-Mediated Protection against Listeria monocytogenes Infection |
| Q55223335 | Designing the new generation of intelligent biocompatible carriers for protein and peptide delivery. |
| Q93167907 | Effect of vaccination with a novel GnRH-based immunocontraceptive on immune responses and fertility in rats |
| Q94669192 | Evaluation of immune response to Bacillus subtilis spores expressing Clonorchis sinensis serpin3 |
| Q88576669 | From allergen to oral vaccine carrier: A new face of ragweed pollen |
| Q89983803 | LPS-binding IgG arrests actively motile Salmonella Typhimurium in gastrointestinal mucus |
| Q46246924 | Maternal Vaccination. Immunization of Sows during Pregnancy against ETEC Infections |
| Q92246549 | Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges |
| Q63740213 | Mucosal vaccines and technology |
| Q52602778 | Noninvasive vaccination against infectious diseases. |
| Q64974251 | Oral Vaccine Delivery for Intestinal Immunity-Biological Basis, Barriers, Delivery System, and M Cell Targeting. |
| Q91962604 | Parenteral-Oral Immunization with Plant-Derived HBcAg as a Potential Therapeutic Vaccine against Chronic Hepatitis B |
| Q56889662 | Peptides as drug delivery vehicles across biological barriers |
| Q91346436 | Plant lyophilisate carrying S-HBsAg as an oral booster vaccine against HBV |
| Q97593286 | Protective antibody response following oral vaccination with microencapsulated Bacillus Anthracis Sterne strain 34F2 spores |
| Q90161931 | Recent Advances in Encapsulation, Protection, and Oral Delivery of Bioactive Proteins and Peptides using Colloidal Systems |
| Q94662613 | Salmonella Enteritidis ghost vaccine carrying the hemagglutinin globular head (HA1) domain from H1N1 virus protects against salmonellosis and influenza in chickens |
| Q92754996 | Surface display of hirame novirhabdovirus (HIRRV) G protein in Lactococcus lactis and its immune protection in flounder (Paralichthys olivaceus) |
Search more.